SEARCH

SEARCH BY CITATION

References

  • Al-Mahdawi S, Pinto RM, Varshney D, Lawrence L, Lowrie MB, Hughes S et al. (2006). GAA repeat expansion mutation mouse models of Friedreich ataxia exhibit oxidative stress leading to progressive neuronal and cardiac pathology. Genomics 88: 580590.
  • Andreux PA, Houtkooper RH, Auwerx J (2013). Pharmacological approaches to restore mitochondrial function. Nat Rev Drug Discov 12: 465483.
  • Aquilano K, Baldelli S, Pagliei B, Cannata SM, Rotilio G, Ciriolo MR (2013). p53 orchestrates the PGC-1alpha-mediated antioxidant response upon mild redox and metabolic imbalance. Antioxid Redox Signal 18: 386399.
  • Arany Z, Lebrasseur N, Morris C, Smith E, Yang W, Ma Y et al. (2007). The transcriptional coactivator PGC-1beta drives the formation of oxidative type IIX fibers in skeletal muscle. Cell Metab 5: 3546.
  • Bass TM, Weinkove D, Houthoofd K, Gems D, Partridge L (2007). Effects of resveratrol on lifespan in Drosophila melanogaster and Caenorhabditis elegans. Mech Ageing Dev 128: 546552.
  • Bastin J, Aubey F, Rötig A, Munnich A, Djouadi F (2008). Activation of peroxisome proliferator-activated receptor pathway stimulates the mitochondrial respiratory chain and can correct deficiencies in patients' cells lacking its components. J Clin Endocrinol Metab 93: 14331441.
  • Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A et al. (2006). Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444: 337342.
  • Bell EL, Guarente L (2011). The SirT3 divining rod points to oxidative stress. Mol Cell 42: 561568.
  • Bell EL, Emerling BM, Ricoult SJ, Guarente L (2011). SirT3 suppresses hypoxia inducible factor 1alpha and tumor growth by inhibiting mitochondrial ROS production. Oncogene 30: 29862996.
  • Bhatt JK, Thomas S, Nanjan MJ (2012). Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr Res 32: 537541.
  • Blanchet J, Longpre F, Bureau G, Morissette M, DiPaolo T, Bronchti G et al. (2008). Resveratrol, a red wine polyphenol, protects dopaminergic neurons in MPTP-treated mice. Prog Neuropsychopharmacol Biol Psychiatry 32: 12431250.
  • Bonnefont JP, Bastin J, Behin A, Djouadi F (2009). Bezafibrate for an inborn mitochondrial beta-oxidation defect. N Engl J Med 360: 838840.
  • Bonnefont JP, Bastin J, Laforet P, Aubey F, Mogenet A, Romano S et al. (2010). Long-term follow-up of bezafibrate treatment in patients with the myopathic form of carnitine palmitoyltransferase 2 deficiency. Clin Pharmacol Ther 88: 101108.
  • Borra MT, Smith BC, Denu JM (2005). Mechanism of human SIRT1 activation by resveratrol. J Biol Chem 280: 1718717195.
  • Brasnyo P, Molnar GA, Mohas M, Marko L, Laczy B, Cseh J et al. (2011). Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr 106: 383389.
  • Bueno Junior CR, Pantaleao LC, Voltarelli VA, Bozi LH, Brum PC, Zatz M (2012). Combined effect of AMPK/PPAR agonists and exercise training in mdx mice functional performance. PLoS One 7: e45699.
  • Burnett C, Valentini S, Cabreiro F, Goss M, Somogyvari M, Piper MD et al. (2011). Absence of effects of Sir2 overexpression on lifespan in C. elegans and Drosophila. Nature 477: 482485.
  • Calvo SE, Compton AG, Hershman SG, Lim SC, Lieber DS, Tucker EJ et al. (2012). Molecular diagnosis of infantile mitochondrial disease with targeted next-generation sequencing. Sci Transl Med 4: 118ra110.
  • Canto C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC et al. (2009). AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 458: 10561060.
  • Canto C, Jiang LQ, Deshmukh AS, Mataki C, Coste A, Lagouge M et al. (2010). Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in skeletal muscle. Cell Metab 11: 213219.
  • Carta AR (2013). PPAR-gamma: therapeutic prospects in Parkinson's disease. Curr Drug Targets 14: 743751.
  • Casarin A, Giorgi G, Pertegato V, Siviero R, Cerqua C, Doimo M et al. (2012). Copper and bezafibrate cooperate to rescue cytochrome c oxidase deficiency in cells of patients with SCO2 mutations. Orphanet J Rare Dis 7: 21.
  • Charach G, Grosskopf I, Rotmensch HH, Kitzis I, Weintraub M (2005). Bezafibrates cause moderate, reversible impairment in renal function in patients without prior renal disease. Nephron Clin Pract 100: c120c125.
  • Chiang MC, Chen CM, Lee MR, Chen HW, Chen HM, Wu YS et al. (2010). Modulation of energy deficiency in Huntington's disease via activation of the peroxisome proliferator-activated receptor gamma. Hum Mol Genet 19: 40434058.
  • Choi JM, Bothwell AL (2012). The nuclear receptor PPARs as important regulators of T-cell functions and autoimmune diseases. Mol Cells 33: 217222.
  • Chouchani ET, Methner C, Nadtochiy SM, Logan A, Pell VR, Ding S et al. (2013). Cardioprotection by S-nitrosation of a cysteine switch on mitochondrial complex I. Nat Med 19: 753759.
  • Corton JM, Gillespie JG, Hawley SA, Hardie DG (1995). 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur J Biochem 229: 558565.
  • Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D (2006). Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 127: 5969.
  • Da Cruz S, Parone PA, Lopes VS, Lillo C, McAlonis-Downes M, Lee SK et al. (2012). Elevated PGC-1alpha activity sustains mitochondrial biogenesis and muscle function without extending survival in a mouse model of inherited ALS. Cell Metab 15: 778786.
  • Dasgupta B, Milbrandt J (2007). Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci U S A 104: 72177222.
  • De Luca A (2012). Pre-clinical drug tests in the mdx mouse as a model of dystrophinopathies: an overview. Acta Myol 31: 4047.
  • De Palma C, Clementi E (2012). Nitric oxide in myogenesis and therapeutic muscle repair. Mol Neurobiol 46: 682692.
  • De Palma C, Falcone S, Pisoni S, Cipolat S, Panzeri C, Pambianco S et al. (2010). Nitric oxide inhibition of Drp1-mediated mitochondrial fission is critical for myogenic differentiation. Cell Death Differ 17: 16841696.
  • De Palma C, Morisi F, Cheli S, Pambianco S, Cappello V, Vezzoli M et al. (2012). Autophagy as a new therapeutic target in Duchenne muscular dystrophy. Cell Death Dis 3: e418.
  • Dell'agnello C, Leo S, Agostino A, Szabadkai G, Tiveron C, Zulian A et al. (2007). Increased longevity and refractoriness to Ca(2+)-dependent neurodegeneration in Surf1 knockout mice. Hum Mol Genet 16: 431444.
  • Diaz F, Thomas CK, Garcia S, Hernandez D, Moraes CT (2005). Mice lacking COX10 in skeletal muscle recapitulate the phenotype of progressive mitochondrial myopathies associated with cytochrome c oxidase deficiency. Hum Mol Genet 14: 27372748.
  • Dillon LM, Hida A, Garcia S, Prolla TA, Moraes CT (2012a). Long-term bezafibrate treatment improves skin and spleen phenotypes of the mtDNA mutator mouse. PLoS One 7: e44335.
  • Dillon LM, Williams SL, Hida A, Peacock JD, Prolla TA, Lincoln J et al. (2012b). Increased mitochondrial biogenesis in muscle improves aging phenotypes in the mtDNA mutator mouse. Hum Mol Genet 21: 22882297.
  • Djouadi F, Bastin J (2011). Species differences in the effects of bezafibrate as a potential treatment of mitochondrial disorders. Cell Metab 14: 715716; author reply 717.
  • Dogan SA, Trifunovic A (2011). Modelling mitochondrial dysfunction in mice. Physiol Res 60 (Suppl 1): S61S70.
  • Dumont M, Stack C, Elipenahli C, Jainuddin S, Gerges M, Starkova N et al. (2012). Bezafibrate administration improves behavioral deficits and tau pathology in P301S mice. Hum Mol Genet 21: 50915105.
  • Dupuis L, Dengler R, Heneka MT, Meyer T, Zierz S, Kassubek J et al. (2012). A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. PLoS One 7: e37885.
  • Egan DF, Shackelford DB, Mihaylova MM, Gelino S, Kohnz RA, Mair W et al. (2011). Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science 331: 456461.
  • El-Hattab AW, Emrick LT, Craigen WJ, Scaglia F (2012). Citrulline and arginine utility in treating nitric oxide deficiency in mitochondrial disorders. Mol Genet Metab 107: 247252.
  • Falk MJ, Pierce EA, Consugar M, Xie MH, Guadalupe M, Hardy O et al. (2012). Mitochondrial disease genetic diagnostics: optimized whole-exome analysis for all MitoCarta nuclear genes and the mitochondrial genome. Discov Med 14: 389399.
  • Feige JN, Lagouge M, Canto C, Strehle A, Houten SM, Milne JC et al. (2008). Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab 8: 347358.
  • Fernandez-Marcos PJ, Auwerx J (2011). Regulation of PGC-1alpha, a nodal regulator of mitochondrial biogenesis. Am J Clin Nutr 93: 884S8890.
  • Fernandez-Marcos PJ, Jeninga EH, Canto C, Harach T, de Boer VC, Andreux P et al. (2012). Muscle or liver-specific Sirt3 deficiency induces hyperacetylation of mitochondrial proteins without affecting global metabolic homeostasis. Sci Rep 2: 425.
  • Finley LW, Carracedo A, Lee J, Souza A, Egia A, Zhang J et al. (2011). SIRT3 opposes reprogramming of cancer cell metabolism through HIF1alpha destabilization. Cancer Cell 19: 416428.
  • Fukui H, Diaz F, Garcia S, Moraes CT (2007). Cytochrome c oxidase deficiency in neurons decreases both oxidative stress and amyloid formation in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 104: 1416314168.
  • Fulco M, Cen Y, Zhao P, Hoffman EP, McBurney MW, Sauve AA et al. (2008). Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 through AMPK-mediated regulation of Nampt. Dev Cell 14: 661673.
  • Giralt A, Villarroya F (2012). SIRT3, a pivotal actor in mitochondrial functions: metabolism, cell death and aging. Biochem J 444: 110.
  • Golubitzky A, Dan P, Weissman S, Link G, Wikstrom JD, Saada A (2011). Screening for active small molecules in mitochondrial complex I deficient patient's fibroblasts, reveals AICAR as the most beneficial compound. PLoS One 6: e26883.
  • Gordon BS, Delgado Diaz DC, Kostek MC (2013). Resveratrol decreases inflammation and increases utrophin gene expression in the mdx mouse model of Duchenne muscular dystrophy. Clin Nutr 32: 104111.
  • Graham BH, Waymire KG, Cottrell B, Trounce IA, MacGregor GR, Wallace DC (1997). A mouse model for mitochondrial myopathy and cardiomyopathy resulting from a deficiency in the heart/muscle isoform of the adenine nucleotide translocator. Nat Genet 16: 226234.
  • Hallows WC, Yu W, Smith BC, Devries MK, Ellinger JJ, Someya S et al. (2011). Sirt3 promotes the urea cycle and fatty acid oxidation during dietary restriction. Mol Cell 41: 139149.
  • Han S, Choi JR, Soon Shin K, Kang SJ (2012). Resveratrol upregulated heat shock proteins and extended the survival of G93A-SOD1 mice. Brain Res 1483: 112117.
  • Handschin C, Kobayashi YM, Chin S, Seale P, Campbell KP, Spiegelman BM (2007). PGC-1alpha regulates the neuromuscular junction program and ameliorates Duchenne muscular dystrophy. Genes Dev 21: 770783.
  • Hardie DG, Carling D, Gamblin SJ (2011). AMP-activated protein kinase: also regulated by ADP? Trends Biochem Sci 36: 470477.
  • Hays T, Rusyn I, Burns AM, Kennett MJ, Ward JM, Gonzalez FJ et al. (2005). Role of peroxisome proliferator-activated receptor-alpha (PPARalpha) in bezafibrate-induced hepatocarcinogenesis and cholestasis. Carcinogenesis 26: 219227.
  • Henin N, Vincent MF, Gruber HE, Van den Berghe G (1995). Inhibition of fatty acid and cholesterol synthesis by stimulation of AMP-activated protein kinase. FASEB J 9: 541546.
  • Henin N, Vincent MF, Van den Berghe G (1996). Stimulation of rat liver AMP-activated protein kinase by AMP analogues. Biochim Biophys Acta 1290: 197203.
  • Herskovits AZ, Guarente L (2013). Sirtuin deacetylases in neurodegenerative diseases of aging. Cell Res 23: 746758.
  • Higashida K, Kim SH, Jung SR, Asaka M, Holloszy JO, Han DH (2013). Effects of resveratrol and SIRT1 on PGC-1alpha activity and mitochondrial biogenesis: a reevaluation. PLoS Biol 11: e1001603.
  • Hirschey MD, Shimazu T, Goetzman E, Jing E, Schwer B, Lombard DB et al. (2010). SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature 464: 121125.
  • Hirschey MD, Shimazu T, Jing E, Grueter CA, Collins AM, Aouizerat B et al. (2011). SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome. Mol Cell 44: 177190.
  • Ho DJ, Calingasan NY, Wille E, Dumont M, Beal MF (2010). Resveratrol protects against peripheral deficits in a mouse model of Huntington's disease. Exp Neurol 225: 7484.
  • Hondares E, Mora O, Yubero P, Rodriguez de la Concepcion M, Iglesias R, Giralt M et al. (2006). Thiazolidinediones and rexinoids induce peroxisome proliferator-activated receptor-coactivator (PGC)-1alpha gene transcription: an autoregulatory loop controls PGC-1alpha expression in adipocytes via peroxisome proliferator-activated receptor-gamma coactivation. Endocrinology 147: 28292838.
  • Hondares E, Pineda-Torra I, Iglesias R, Staels B, Villarroya F, Giralt M (2007). PPARdelta, but not PPARalpha, activates PGC-1alpha gene transcription in muscle. Biochem Biophys Res Commun 354: 10211027.
  • Hondares E, Rosell M, Diaz-Delfin J, Olmos Y, Monsalve M, Iglesias R et al. (2011). Peroxisome proliferator-activated receptor alpha (PPARalpha) induces PPARgamma coactivator 1alpha (PGC-1alpha) gene expression and contributes to thermogenic activation of brown fat: involvement of PRDM16. J Biol Chem 286: 4311243122.
  • Hori YS, Kuno A, Hosoda R, Tanno M, Miura T, Shimamoto K et al. (2011). Resveratrol ameliorates muscular pathology in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy. J Pharmacol Exp Ther 338: 784794.
  • Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG et al. (2003). Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425: 191196.
  • Hubbard BP, Gomes AP, Dai H, Li J, Case AW, Considine T et al. (2013). Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science 339: 12161219.
  • Jager S, Handschin C, St-Pierre J, Spiegelman BM (2007). AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl Acad Sci U S A 104: 1201712022.
  • Jahnke VE, Van Der Meulen JH, Johnston HK, Ghimbovschi S, Partridge T, Hoffman EP et al. (2012). Metabolic remodeling agents show beneficial effects in the dystrophin-deficient mdx mouse model. Skelet Muscle 2: 16.
  • Jin J, Albertz J, Guo Z, Peng Q, Rudow G, Troncoso JC et al. (2013). Neuroprotective effects of PPAR-gamma agonist rosiglitazone in N171-82Q mouse model of Huntington's disease. J Neurochem 125: 410419.
  • Jing E, Emanuelli B, Hirschey MD, Boucher J, Lee KY, Lombard D et al. (2011). Sirtuin-3 (Sirt3) regulates skeletal muscle metabolism and insulin signaling via altered mitochondrial oxidation and reactive oxygen species production. Proc Natl Acad Sci U S A 108: 1460814613.
  • Jing E, O'Neill BT, Rardin MJ, Kleinridders A, Ilkeyeva OR, Ussar S et al. (2013). Sirt3 regulates metabolic flexibility of skeletal muscle through reversible enzymatic deacetylation. Diabetes 62: 34043417.
  • Johri A, Calingasan NY, Hennessey TM, Sharma A, Yang L, Wille E et al. (2012). Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease. Hum Mol Genet 21: 11241137.
  • Joseph AM, Joanisse DR, Baillot RG, Hood DA (2012). Mitochondrial dysregulation in the pathogenesis of diabetes: potential for mitochondrial biogenesis-mediated interventions. Exp Diabetes Res 2012: 642038.
  • Kaeberlein M, McDonagh T, Heltweg B, Hixon J, Westman EA, Caldwell SD et al. (2005). Substrate-specific activation of sirtuins by resveratrol. J Biol Chem 280: 1703817045.
  • Karuppagounder SS, Pinto JT, Xu H, Chen HL, Beal MF, Gibson GE (2009). Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem Int 54: 111118.
  • Kiaei M, Kipiani K, Chen J, Calingasan NY, Beal MF (2005). Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp Neurol 191: 331336.
  • Kim D, Nguyen MD, Dobbin MM, Fischer A, Sananbenesi F, Rodgers JT et al. (2007). SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J 26: 31693179.
  • Kim J, Kundu M, Viollet B, Guan KL (2011). AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol 13: 132141.
  • Kobilo T, Yuan C, van Praag H (2011). Endurance factors improve hippocampal neurogenesis and spatial memory in mice. Learn Mem 18: 103107.
  • Koene S, Smeitink J (2011). Metabolic manipulators: a well founded strategy to combat mitochondrial dysfunction. J Inherit Metab Dis 34: 315325.
  • Koga Y, Akita Y, Nishioka J, Yatsuga S, Povalko N, Tanabe Y et al. (2005). L-arginine improves the symptoms of strokelike episodes in MELAS. Neurology 64: 710712.
  • Komen JC, Thorburn DR (2012). Modeling mitochondrial dysfunction in neurodegenerative disease. In: Reeve AK, Krishnan KJ, Duchen MR, Turnbull DM (eds). Mitochondrial Dysfunction in Neurodegenerative Disorders. Springer: London, pp. 193212.
  • Kujoth GC, Hiona A, Pugh TD, Someya S, Panzer K, Wohlgemuth SE et al. (2005). Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science 309: 481484.
  • Kuno A, Hori YS, Hosoda R, Tanno M, Miura T, Shimamoto K et al. (2013). Resveratrol improves cardiomyopathy in dystrophin-deficient mice through SIRT1 protein-mediated modulation of p300 protein. J Biol Chem 288: 59635972.
  • Kuznetsov AV, Winkler K, Wiedemann FR, von Bossanyi P, Dietzmann K, Kunz WS (1998). Impaired mitochondrial oxidative phosphorylation in skeletal muscle of the dystrophin-deficient mdx mouse. Mol Cell Biochem 183: 8796.
  • Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F et al. (2006). Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127: 11091122.
  • Lai L, Leone TC, Zechner C, Schaeffer PJ, Kelly SM, Flanagan DP et al. (2008). Transcriptional coactivators PGC-1alpha and PGC-lbeta control overlapping programs required for perinatal maturation of the heart. Genes Dev 22: 19481961.
  • Lehman JJ, Barger PM, Kovacs A, Saffitz JE, Medeiros DM, Kelly DP (2000). Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. J Clin Invest 106: 847856.
  • Leone TC, Lehman JJ, Finck BN, Schaeffer PJ, Wende AR, Boudina S et al. (2005). PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol 3: e101.
  • Lerin C, Rodgers JT, Kalume DE, Kim SH, Pandey A, Puigserver P (2006). GCN5 acetyltransferase complex controls glucose metabolism through transcriptional repression of PGC-1alpha. Cell Metab 3: 429438.
  • Li L, Voullaire L, Sandi C, Pook MA, Ioannou PA, Delatycki MB et al. (2013). Pharmacological screening using an FXN-EGFP cellular genomic reporter assay for the therapy of Friedreich ataxia. PLoS One 8: e55940.
  • Li X, Monks B, Ge Q, Birnbaum MJ (2007). Akt/PKB regulates hepatic metabolism by directly inhibiting PGC-1alpha transcription coactivator. Nature 447: 10121016.
  • Liang H, Ward WF, Jang YC, Bhattacharya A, Bokov AF, Li Y et al. (2011). PGC-1alpha protects neurons and alters disease progression in an amyotrophic lateral sclerosis mouse model. Muscle Nerve 44: 947956.
  • Lin J, Wu H, Tarr PT, Zhang CY, Wu Z, Boss O et al. (2002). Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature 418: 797801.
  • Lin J, Wu PH, Tarr PT, Lindenberg KSS, Pierre J, Zhang CY et al. (2004). Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell 119: 121135.
  • Lin MT, Beal MF (2006). Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443: 787795.
  • Lira VA, Brown DL, Lira AK, Kavazis AN, Soltow QA, Zeanah EH et al. (2010). Nitric oxide and AMPK cooperatively regulate PGC-1 in skeletal muscle cells. J Physiol 588: 35513566.
  • Ljubicic V, Miura P, Burt M, Boudreault L, Khogali S, Lunde JA et al. (2011). Chronic AMPK activation evokes the slow, oxidative myogenic program and triggers beneficial adaptations in mdx mouse skeletal muscle. Hum Mol Genet 20: 34783493.
  • Lofrumento DD, Nicolardi G, Cianciulli A, De Nuccio F, La Pesa V, Carofiglio V et al. (2013). Neuroprotective effects of resveratrol in an MPTP mouse model of Parkinson's-like disease: possible role of SOCS-1 in reducing pro-inflammatory responses. Innate Immun. DOI:10.1177/1753425913488429
  • McConell GK, Ng GP, Phillips M, Ruan Z, Macaulay SL, Wadley GD (2010). Central role of nitric oxide synthase in AICAR and caffeine-induced mitochondrial biogenesis in L6 myocytes. J Appl Physiol 108: 589595.
  • Mandrekar P, Ambade A, Lim A, Szabo G, Catalano D (2011). An essential role for monocyte chemoattractant protein-1 in alcoholic liver injury: regulation of proinflammatory cytokines and hepatic steatosis in mice. Hepatology 54: 21852197.
  • Marangos PJ, Loftus T, Wiesner J, Lowe T, Rossi E, Browne CE et al. (1990). Adenosinergic modulation of homocysteine-induced seizures in mice. Epilepsia 31: 239246.
  • Markert CD, Kim E, Gifondorwa DJ, Childers MK, Milligan CE (2010). A single-dose resveratrol treatment in a mouse model of amyotrophic lateral sclerosis. J Med Food 13: 10811085.
  • Merrill GF, Kurth EJ, Hardie DG, Winder WW (1997). AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. Am J Physiol Endocrinol Metab 273: E1107E1112.
  • Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ et al. (2007). Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450: 712716.
  • Miura P, Chakkalakal JV, Boudreault L, Belanger G, Hebert RL, Renaud JM et al. (2009). Pharmacological activation of PPARbeta/delta stimulates utrophin A expression in skeletal muscle fibers and restores sarcolemmal integrity in mature mdx mice. Hum Mol Genet 18: 46404649.
  • Monsalve FA, Pyarasani RD, Delgado-Lopez F, Moore-Carrasco R (2013). Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases. Mediators Inflamm 2013: 549627.
  • Mudo G, Makela J, Di Liberto V, Tselykh TV, Olivieri M, Piepponen P et al. (2012). Transgenic expression and activation of PGC-1alpha protect dopaminergic neurons in the MPTP mouse model of Parkinson's disease. Cell Mol Life Sci 69: 11531165.
  • Nakajima T, Tanaka N, Kanbe H, Hara A, Kamijo Y, Zhang X et al. (2009). Bezafibrate at clinically relevant doses decreases serum/liver triglycerides via down-regulation of sterol regulatory element-binding protein-1c in mice: a novel peroxisome proliferator-activated receptor alpha-independent mechanism. Mol Pharmacol 75: 782792.
  • Napolitano M, Costa L, Palermo R, Giovenco A, Vacca A, Gulino A (2011). Protective effect of pioglitazone, a PPARgamma ligand, in a 3 nitropropionic acid model of Huntington's disease. Brain Res Bull 85: 231237.
  • Narkar VA, Downes M, Yu RT, Embler E, Wang YX, Banayo E et al. (2008). AMPK and PPARdelta agonists are exercise mimetics. Cell 134: 405415.
  • Nisoli E, Carruba MO (2006). Nitric oxide and mitochondrial biogenesis. J Cell Sci 119: 28552862.
  • Nisoli E, Clementi E, Paolucci C, Cozzi V, Tonello C, Sciorati C et al. (2003). Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. Science 299: 896899.
  • Noe N, Dillon L, Lellek V, Diaz F, Hida A, Moraes CT et al. (2013). Bezafibrate improves mitochondrial function in the CNS of a mouse model of mitochondrial encephalopathy. Mitochondrion 13: 417426.
  • Oakhill JS, Scott JW, Kemp BE (2012). AMPK functions as an adenylate charge-regulated protein kinase. Trends Endocrinol Metab 23: 125132.
  • Olson EJ, Pearce GL, Jones NP, Sprecher DL (2012). Lipid effects of peroxisome proliferator-activated receptor-delta agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome. Arterioscler Thromb Vasc Biol 32: 22892294.
  • Pacholec M, Bleasdale JE, Chrunyk B, Cunningham D, Flynn D, Garofalo RS et al. (2010). SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem 285: 83408351.
  • Park SJ, Ahmad F, Philp A, Baar K, Williams T, Luo H et al. (2012). Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 148: 421433.
  • Patel KR, Scott E, Brown VA, Gescher AJ, Steward WP, Brown K (2011). Clinical trials of resveratrol. Ann N Y Acad Sci 1215: 161169.
  • Pauly M, Daussin F, Burelle Y, Li T, Godin R, Fauconnier J et al. (2012). AMPK activation stimulates autophagy and ameliorates muscular dystrophy in the mdx mouse diaphragm. Am J Pathol 181: 583592.
  • Pearson KJ, Baur JA, Lewis KN, Peshkin L, Price NL, Labinskyy N et al. (2008). Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab 8: 157168.
  • Pfeffer G, Chinnery PF (2013). Diagnosis and treatment of mitochondrial myopathies. Ann Med 45: 416.
  • Pfeffer G, Majamaa K, Turnbull DM, Thorburn D, Chinnery PF (2012). Treatment for mitochondrial disorders. Cochrane Database Syst Rev (4): CD004426.
  • Pirinen E, Lo Sasso G, Auwerx J (2012). Mitochondrial sirtuins and metabolic homeostasis. Best Pract Res Clin Endocrinol Metab 26: 759770.
  • Poulsen L, Siersbaek M, Mandrup S (2012). PPARs: fatty acid sensors controlling metabolism. Semin Cell Dev Biol 23: 631639.
  • Poulsen MM, Vestergaard PF, Clasen BF, Radko Y, Christensen LP, Stodkilde-Jorgensen H et al. (2013). High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 62: 11861195.
  • Price NL, Gomes AP, Ling AJ, Duarte FV, Martin-Montalvo A, North BJ et al. (2012). SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab 15: 675690.
  • Qiu X, Brown K, Hirschey MD, Verdin E, Chen D (2010). Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation. Cell Metab 12: 662667.
  • Rardin MJ, Newman JC, Held JM, Cusack MP, Sorensen DJ, Li B et al. (2013). Label-free quantitative proteomics of the lysine acetylome in mitochondria identifies substrates of SIRT3 in metabolic pathways. Proc Natl Acad Sci U S A 110: 66016606.
  • Ridder DA, Schwaninger M (2012). In search of the neuroprotective mechanism of thiazolidinediones in Parkinson's disease. Exp Neurol 238: 133137.
  • Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P (2005). Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 434: 113118.
  • Russell LK, Mansfield CM, Lehman JJ, Kovacs A, Courtois M, Saffitz JE et al. (2004). Cardiac-specific induction of the transcriptional coactivator peroxisome proliferator-activated receptor gamma coactivator-1alpha promotes mitochondrial biogenesis and reversible cardiomyopathy in a developmental stage-dependent manner. Circ Res 94: 525533.
  • Safdar A, Bourgeois JM, Ogborn DI, Little JP, Hettinga BP, Akhtar M et al. (2011). Endurance exercise rescues progeroid aging and induces systemic mitochondrial rejuvenation in mtDNA mutator mice. Proc Natl Acad Sci U S A 108: 41354140.
  • Scarpulla RC (2011). Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network. Biochim Biophys Acta 1813: 12691278.
  • Scarpulla RC (2012). Nucleus-encoded regulators of mitochondrial function: integration of respiratory chain expression, nutrient sensing and metabolic stress. Biochim Biophys Acta 1819: 10881097.
  • Scarpulla RC, Vega RB, Kelly DP (2012). Transcriptional integration of mitochondrial biogenesis. Trends Endocrinol Metab 23: 459466.
  • Schon EA, DiMauro S, Hirano M, Gilkerson RW (2010). Therapeutic prospects for mitochondrial disease. Trends Mol Med 16: 268276.
  • Schulz TJ, Huang P, Huang TL, Xue R, McDougall LE, Townsend KL et al. (2013). Brown-fat paucity due to impaired BMP signalling induces compensatory browning of white fat. Nature 495: 379383.
  • Schutz B, Reimann J, Dumitrescu-Ozimek L, Kappes-Horn K, Landreth GE, Schurmann B et al. (2005). The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J Neurosci 25: 78057812.
  • Selsby JT, Morine KJ, Pendrak K, Barton ER, Sweeney HL (2012). Rescue of dystrophic skeletal muscle by PGC-1alpha involves a fast to slow fiber type shift in the mdx mouse. PLoS One 7: e30063.
  • Shimazu T, Hirschey MD, Hua L, Dittenhafer-Reed KE, Schwer B, Lombard DB et al. (2010). SIRT3 deacetylates mitochondrial 3-hydroxy-3-methylglutaryl CoA synthase 2 and regulates ketone body production. Cell Metab 12: 654661.
  • Skladal D, Halliday J, Thorburn DR (2003). Minimum birth prevalence of mitochondrial respiratory chain disorders in children. Brain 126: 19051912.
  • Someya S, Yu W, Hallows WC, Xu J, Vann JM, Leeuwenburgh C et al. (2010). Sirt3 mediates reduction of oxidative damage and prevention of age-related hearing loss under caloric restriction. Cell 143: 802812.
  • Srivastava S, Diaz F, Iommarini L, Aure K, Lombes A, Moraes CT (2009). PGC-1α/β induced expression partially compensates for respiratory chain defects in cells from patients with mitochondrial disorders. Human Molecular Genetics 18: 18051812.
  • St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, Jager S et al. (2006). Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 127: 397408.
  • Sullivan JE, Brocklehurst KJ, Marley AE, Carey F, Carling D, Beri RK (1994). Inhibition of lipolysis and lipogenesis in isolated rat adipocytes with AICAR, a cell-permeable activator of AMP-activated protein kinase. FEBS Lett 353: 3336.
  • Sundaresan NR, Gupta M, Kim G, Rajamohan SB, Isbatan A, Gupta MP (2009). Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice. J Clin Invest 119: 27582771.
  • Suomalainen A (2011). Therapy for mitochondrial disorders: little proof, high research activity, some promise. Semin Fetal Neonatal Med 16: 236240.
  • Szendroedi J, Phielix E, Roden M (2012). The role of mitochondria in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol 8: 92103.
  • Tenenbaum A, Motro M, Fisman EZ (2005). Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetol 4: 14.
  • Tengan CH, Rodrigues GS, Godinho RO (2012). Nitric oxide in skeletal muscle: role on mitochondrial biogenesis and function. Int J Mol Sci 13: 1716017184.
  • Timmers S, Konings E, Bilet L, Houtkooper RH, van de Weijer T, Goossens GH et al. (2011). Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 14: 612622.
  • Torraco A, Diaz F, Vempati UD, Moraes CT (2009). Mouse models of oxidative phosphorylation defects: powerful tools to study the pathobiology of mitochondrial diseases. Biochim Biophys Acta 1793: 171180.
  • Trifunovic A, Wredenberg A, Falkenberg M, Spelbrink JN, Rovio AT, Bruder CE et al. (2004). Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature 429: 417423.
  • Tyynismaa H, Mjosund KP, Wanrooij S, Lappalainen I, Ylikallio E, Jalanko A et al. (2005). Mutant mitochondrial helicase Twinkle causes multiple mtDNA deletions and a late-onset mitochondrial disease in mice. Proc Natl Acad Sci U S A 102: 1768717692.
  • Um JH, Park SJ, Kang H, Yang S, Foretz M, McBurney MW et al. (2010). AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 59: 554563.
  • Verdin E, Hirschey MD, Finley LW, Haigis MC (2010). Sirtuin regulation of mitochondria: energy production, apoptosis, and signaling. Trends Biochem Sci 35: 669675.
  • Vingtdeux V, Giliberto L, Zhao H, Chandakkar P, Wu Q, Simon JE et al. (2010). AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J Biol Chem 285: 91009113.
  • Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F (2012). Cellular and molecular mechanisms of metformin: an overview. Clin Sci 122: 253270.
  • Viscomi C, Bottani E, Civiletto G, Cerutti R, Moggio M, Fagiolari G et al. (2011). In vivo correction of COX deficiency by activation of the AMPK/PGC-1α axis. Cell Metab 14: 8090.
  • Wallace DC, Fan W, Procaccio V (2010). Mitochondrial energetics and therapeutics. Annu Rev Pathol 5: 297348.
  • Wenz T (2013). Regulation of mitochondrial biogenesis and PGC-1α under cellular stress. Mitochondrion 13: 134142.
  • Wenz T, Diaz F, Spiegelman BM, Moraes CT (2008). Activation of the PPAR/PGC-1alpha pathway prevents a bioenergetic deficit and effectively improves a mitochondrial myopathy phenotype. Cell Metab 8: 249256.
  • Wenz T, Diaz F, Hernandez D, Moraes CT (2009a). Endurance exercise is protective for mice with mitochondrial myopathy. J Appl Physiol 106: 17121719.
  • Wenz T, Rossi SG, Rotundo RL, Spiegelman BM, Moraes CT (2009b). Increased muscle PGC-1alpha expression protects from sarcopenia and metabolic disease during aging. Proc Natl Acad Sci U S A 106: 2040520410.
  • Westerheide SD, Anckar J, Stevens SM Jr, Sistonen L, Morimoto RI (2009). Stress-inducible regulation of heat shock factor 1 by the deacetylase SIRT1. Science 323: 10631066.
  • Weydt P, Pineda VV, Torrence AE, Libby RT, Satterfield TF, Lazarowski ER et al. (2006). Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metab 4: 349362.
  • Winder WW, Holmes BF, Rubink DS, Jensen EB, Chen M, Holloszy JO (2000). Activation of AMP-activated protein kinase increases mitochondrial enzymes in skeletal muscle. J Appl Physiol 88: 22192226.
  • Wong LJ (2013). Next generation molecular diagnosis of mitochondrial disorders. Mitochondrion 13: 379387.
  • Wood JG, Rogina B, Lavu S, Howitz K, Helfand SL, Tatar M et al. (2004). Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 430: 686689.
  • Wu J, Song Y, Li H, Chen J (2009). Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report. Eur J Clin Pharmacol 65: 11691174.
  • Wu J, Cohen P, Spiegelman BM (2013). Adaptive thermogenesis in adipocytes: is beige the new brown? Genes Dev 27: 234250.
  • Yang H, Brosel S, Acin-Perez R, Slavkovich V, Nishino I, Khan R et al. (2010). Analysis of mouse models of cytochrome c oxidase deficiency owing to mutations in Sco2. Hum Mol Genet 19: 170180.
  • Yang Q, Nagano T, Shah Y, Cheung C, Ito S, Gonzalez FJ (2008). The PPAR alpha-humanized mouse: a model to investigate species differences in liver toxicity mediated by PPAR alpha. Toxicol Sci 101: 132139.
  • Yatsuga S, Suomalainen A (2012). Effect of bezafibrate treatment on late-onset mitochondrial myopathy in mice. Hum Mol Genet 21: 526535.
  • Ylikallio E, Suomalainen A (2012). Mechanisms of mitochondrial diseases. Ann Med 44: 4159.
  • Yoshino J, Conte C, Fontana L, Mittendorfer B, Imai S, Schechtman KB et al. (2012). Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metab 16: 658664.
  • Yu-Wai-Man P, Griffiths PG, Chinnery PF (2011). Mitochondrial optic neuropathies – disease mechanisms and therapeutic strategies. Prog Retin Eye Res 30: 81114.
  • Zang M, Xu S, Maitland-Toolan KA, Zuccollo A, Hou X, Jiang B et al. (2006). Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes 55: 21802191.
  • Zhao W, Varghese M, Yemul S, Pan Y, Cheng A, Marano P et al. (2011). Peroxisome proliferator activator receptor gamma coactivator-1alpha (PGC-1alpha) improves motor performance and survival in a mouse model of amyotrophic lateral sclerosis. Mol Neurodegener 6: 51.